YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification

Oncogene

Volumn 30, Issue 34, 2011, Pages 3649-3660

  Davies, A H ^a   Barrett, I ^b   Pambid, M R ^a   Hu, K ^a   Stratford, A L ^a   Freeman, S ^c   Berquin, I M ^d   Pelech, S ^e,f   Hieter, P ^b   Maxwell, C ^c   Dunn, S E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Kinexus Bioinformatics Corporation   (Canada)

Author keywords

breast cancer; cell cycle; centrosome; HER2 amplification; premalignancy; YB 1

Indexed keywords

ANTIBODY; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA TUBULIN; LIM KINASE; LIM KINASE 1; Y BOX BINDING PROTEIN 1;

ARTICLE; BREAST CANCER; BREAST CELL; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CENTROSOME; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOKINESIS; EPITHELIUM CELL; GENE AMPLIFICATION; GENE FUNCTION; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANEUPLOIDY; CELL CYCLE; DISEASE SUSCEPTIBILITY; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MITOSIS; NEOPLASMS; Y-BOX-BINDING PROTEIN 1;

EID: 80052065124     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.82     Document Type: Article

References (52)

1. Alliegro MC, Alliegro MA, Palazzo RE. (2006). Centrosome-associated RNA in surf clam oocytes. Proc Natl Acad Sci USA 103: 9034-9038. (Pubitemid 43902528)
2. Amano T, Kaji N, Ohashi K, Mizuno K. (2002). Mitosis-specific activation of LIM motif-containing protein kinase and roles of cofilin phosphorylation and dephosphorylation in mitosis. J Biol Chem 277: 22093-22102. (Pubitemid 34952364)
3. Band V, Zajchowski D, Kulesa V, Sager R (1990). Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci USA 87: 463-467.
4. Barber TD, McManus K, Yuen KW, Reis M, Parmigiani G, Shen D et al. (2008). Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci USA 105: 3443-3448. (Pubitemid 351723572)
5. Basaki Y, Taguchi K, Izumi H, Murakami Y, Kubo T, Hosoi F et al. (2010). Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. Eur J Cancer 46: 954-965.
6. Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, Khodjakov A et al. (2008). Centrosome amplification can initiate tumorigenesis in flies. Cell 133: 1032-1042. (Pubitemid 351787756)
7. Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D et al. (2005). YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 65: 4078-4087. (Pubitemid 40775644)
8. Bernard O. (2007). Lim kinases, regulators of actin dynamics. Int J Biochem Cell Biol 39: 1071-1076. (Pubitemid 46819128)
9. Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP et al. (2005). Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 24: 3177-3186. (Pubitemid 40695086)
10. Bouvet P, Matsumoto K, Wolffe AP. (1995). Sequence-specific RNA recognition by the xenopus Y-box proteins. An essential role for the cold shock domain. J Biol Chem 270: 28297-28303.
11. Chakrabarti R, Jones JL, Oelschlager DK, Tapia T, Tousson A, Grizzle WE. (2007). Phosphorylated LIM kinases colocalize with gamma-tubulin in centrosomes during early stages of mitosis. Cell Cycle 6: 2944-2952.
12. Davila M, Jhala D, Ghosh D, Grizzle WE, Chakrabarti R. (2007). Expression of LIM kinase 1 is associated with reversible G1/S phase arrest, chromosomal instability and prostate cancer. Mol Cancer 6: 40.
13. Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE. (2010). The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene 29: 6294-6300.
14. Dimri G, Band H, Band V. (2005). Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Res 7: 171-179. (Pubitemid 40872783)
15. Dumont N, Crawford YG, Sigaroudinia M, Nagrani SS, Wilson MB, Buehring GC et al. (2009). Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy. Breast Cancer Res 11: R87.
16. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL et al. (2001). Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15: 50-65. (Pubitemid 32060682)
17. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D et al. (2009). Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 15: 402-415.
18. Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y et al. (2009). Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 28: 1421-1431.
19. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. (2005). Cytokinesis failure generating tetraploids promotes tumor-igenesis in p53-null cells. Nature 437: 1043-1047. (Pubitemid 41486987)
20. Fukasawa K. (2007). Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer 7: 911-924. (Pubitemid 350165854)
21. Ganem NJ, Godinho SA, Pellman D. (2009). A mechanism linking extra centrosomes to chromosomal instability. Nature 460: 278-282.
22. Gaudreault I, Guay D, Lebel M. (2004). YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res 32: 316-327. (Pubitemid 38228631)
23. Guay D, Gaudreault I, Massip L, Lebel M. (2006). Formation of a nuclear complex containing the p53 tumor suppressor, YB-1, and the werner syndrome gene product in cells treated with UV light. Int J Biochem Cell Biol 38: 1300-1313.
24. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D et al. (2008). Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: R86.
25. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
26. Holland AJ, Cleveland DW. (2009). Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 10: 478-487.
27. Ise T, Nagatani G, Imamura T, Kato K, Takano H, Nomoto M et al. (1999). Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 59: 342-346. (Pubitemid 29048865)
28. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K et al. (2002). Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 97: 278-282. (Pubitemid 34049016)
29. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I et al. (2003). YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 278: 27988-27996. (Pubitemid 36899994)
30. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. (2003). The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25: 691-698. (Pubitemid 36850797)
31. Lee C, Dhillon J, Wang MY, Gao Y, Hu K, Park E et al. (2008). Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 68: 8661-8666.
32. Nigg EA. (2006). Origins and consequences of centrosome aberrations in human cancers. Int J Cancer 119: 2717-2723. (Pubitemid 44846221)
33. Nigg EA. (2002). Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2: 815-825. (Pubitemid 37328900)
34. Nigg EA, Raff JW. (2009). Centrioles, centrosomes, and cilia in health and disease. Cell 139: 663-678.
35. Raouf A, Brown L, Vrcelj N, To K, Kwok W, Huntsman D et al. (2005). Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst 97: 1302-1306. (Pubitemid 41535371)
36. Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD. (2001). Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409: 633-637. (Pubitemid 32154817)
37. Scully R. (2000). Role of BRCA gene dysfunction in breast and ovarian cancer predisposition. Breast Cancer Res 2: 324-330. (Pubitemid 32223614)
38. Shi Q, King RW. (2005). Chromosome nondisjunction yields tetra-ploid rather than aneuploid cells in human cell lines. Nature 437: 1038-1042. (Pubitemid 41486986)
39. Shibao K, Takano H, Nakayama Y, Okazaki K, Nagata N, Izumi H et al. (1999). Enhanced coexpression of YB-1 and DNA topo-isomerase II alpha genes in human colorectal carcinomas. Int J Cancer 83: 732-737.
40. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
41. Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y et al. (2008). Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 10: R99.
42. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E et al. (2007). Epidermal growth factor receptor (EGFR) is transcription-ally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 9: R61.
43. Sumi T, Hashigasako A, Matsumoto K, Nakamura T. (2006). Different activity regulation and subcellular localization of LIMK1 and LIMK2 during cell cycle transition. Exp Cell Res 312: 1021-1030.
44. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E et al. (2005). Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-4292. (Pubitemid 40961781)
45. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. (2005). Polo-like kinases (plks) and cancer. Oncogene 24: 287-291. (Pubitemid 40188609)
46. Tlsty TD, Crawford YG, Holst CR, Fordyce CA, Zhang J, McDermott K et al. (2004). Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia 9: 263-274. (Pubitemid 39545743)
47. To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J et al. (2010). Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 70: 2840-2851.
48. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T et al. (2006). Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25: 7148-7158. (Pubitemid 44764184)
49. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E et al. (2006). Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 66: 4872-4879.
50. Yang X, Yu K, Hao Y, Li DM, Stewart R, Insogna KL et al. (2004). LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1. Nat Cell Biol 6: 609-617. (Pubitemid 38960918)
51. Yoshioka K, Foletta V, Bernard O, Itoh K. (2003). A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 100: 7247-7252. (Pubitemid 36706424)
52. Yu YN, Yip GW, Tan PH, Thike AA, Matsumoto K, Tsujimoto M et al. (2010). Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. Int J Oncol 37: 483-492.